NO300911B1 - Fremgangsmåte for inaktivering av virus i blod og blodprodukter - Google Patents
Fremgangsmåte for inaktivering av virus i blod og blodprodukter Download PDFInfo
- Publication number
- NO300911B1 NO300911B1 NO920834A NO920834A NO300911B1 NO 300911 B1 NO300911 B1 NO 300911B1 NO 920834 A NO920834 A NO 920834A NO 920834 A NO920834 A NO 920834A NO 300911 B1 NO300911 B1 NO 300911B1
- Authority
- NO
- Norway
- Prior art keywords
- blood
- dye
- added
- plasma
- dyes
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 20
- 239000010836 blood and blood product Substances 0.000 title claims abstract description 15
- 241000700605 Viruses Species 0.000 title claims description 33
- 230000000415 inactivating effect Effects 0.000 title claims description 7
- 210000004369 blood Anatomy 0.000 claims abstract description 21
- 239000008280 blood Substances 0.000 claims abstract description 20
- 239000003463 adsorbent Substances 0.000 claims abstract description 16
- 230000008569 process Effects 0.000 claims abstract description 3
- 239000000975 dye Substances 0.000 claims description 52
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims description 36
- 229960000907 methylthioninium chloride Drugs 0.000 claims description 36
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 claims description 19
- 229950000688 phenothiazine Drugs 0.000 claims description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- 229940125691 blood product Drugs 0.000 claims description 9
- 238000000926 separation method Methods 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 229950003937 tolonium Drugs 0.000 claims description 5
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 229920006222 acrylic ester polymer Polymers 0.000 claims description 2
- 229920003053 polystyrene-divinylbenzene Polymers 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 238000010257 thawing Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 3
- 238000000746 purification Methods 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 description 24
- 230000002779 inactivation Effects 0.000 description 17
- 102000004506 Blood Proteins Human genes 0.000 description 14
- 108010017384 Blood Proteins Proteins 0.000 description 14
- 241000711975 Vesicular stomatitis virus Species 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 9
- 239000011148 porous material Substances 0.000 description 9
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 8
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 8
- 239000003114 blood coagulation factor Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000012460 protein solution Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000701161 unidentified adenovirus Species 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000008033 biological extinction Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 244000309711 non-enveloped viruses Species 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 230000000274 adsorptive effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 2
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 2
- 208000017983 photosensitivity disease Diseases 0.000 description 2
- 231100000434 photosensitization Toxicity 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000001408 Carbon monoxide poisoning Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000009474 immediate action Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- NKAAEMMYHLFEFN-UHFFFAOYSA-M monosodium tartrate Chemical compound [Na+].OC(=O)C(O)C(O)C([O-])=O NKAAEMMYHLFEFN-UHFFFAOYSA-M 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- -1 oxygen radicals Chemical class 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 238000007539 photo-oxidation reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/08—Radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0209—Multiple bag systems for separating or storing blood components
- A61M1/0218—Multiple bag systems for separating or storing blood components with filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
- A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
- A61M1/3686—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents by removing photoactive agents after irradiation
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3930510A DE3930510A1 (de) | 1989-09-13 | 1989-09-13 | Verfahren zur inaktivierung von viren in blut und blutprodukten |
| PCT/DE1990/000691 WO1991003933A1 (de) | 1989-09-13 | 1990-09-08 | Verfahren zur inaktivierung von viren in blut und blutprodukten |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO920834D0 NO920834D0 (no) | 1992-03-03 |
| NO920834L NO920834L (no) | 1992-03-03 |
| NO300911B1 true NO300911B1 (no) | 1997-08-18 |
Family
ID=6389298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO920834A NO300911B1 (no) | 1989-09-13 | 1992-03-03 | Fremgangsmåte for inaktivering av virus i blod og blodprodukter |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP0491757B2 (fi) |
| JP (1) | JP2965695B2 (fi) |
| AT (1) | ATE161681T1 (fi) |
| AU (1) | AU635068B2 (fi) |
| CA (1) | CA2065842C (fi) |
| CS (1) | CS76692A3 (fi) |
| DE (3) | DE3930510A1 (fi) |
| DK (1) | DK0491757T4 (fi) |
| ES (1) | ES2113347T5 (fi) |
| FI (1) | FI99192C (fi) |
| HU (1) | HU215131B (fi) |
| NO (1) | NO300911B1 (fi) |
| RU (1) | RU2036235C1 (fi) |
| WO (1) | WO1991003933A1 (fi) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5571666A (en) * | 1988-10-28 | 1996-11-05 | Oklahoma Medical Research Foundation | Thiazine dyes used to inactivate HIV in biological fluids |
| US6348309B1 (en) * | 1989-09-13 | 2002-02-19 | Blutspendedienst Der Landesverbaende Des Deutschen Roten Kreuzes Niedersachsen, Oldenburg Und Bremen G.G.M.B.H. | Process for inactivating viruses in blood and blood products |
| US6251644B1 (en) | 1990-04-16 | 2001-06-26 | Baxter International, Inc. | Method for inactivating non-enveloped viral contaminants with a photosensitizer by increasing viral permeability to the photosensitizer |
| US6187572B1 (en) | 1990-04-16 | 2001-02-13 | Baxter International Inc. | Method of inactivation of viral and bacterial blood contaminants |
| US5120649A (en) * | 1990-05-15 | 1992-06-09 | New York Blood Center, Inc. | Photodynamic inactivation of viruses in blood cell-containing compositions |
| DE9102709U1 (de) * | 1991-03-07 | 1991-05-23 | Blutspendedienst der Landesverbände des Deutschen Roten Kreuzes Niedersachsen, Oldenburg und Bremen Gemeinnützige GmbH, 3257 Springe | Blutbeutelanordnung |
| AU4107396A (en) | 1992-03-02 | 1996-06-06 | Cerus Corporation | Synthetic media for blood components |
| US6433343B1 (en) | 1992-03-02 | 2002-08-13 | Cerus Corporation | Device and method for photoactivation |
| US6207107B1 (en) * | 1992-10-05 | 2001-03-27 | Baxter International Inc. | Steam sterilizable system for inactivating viral contaminants in body fluids |
| EP0707633A4 (en) * | 1993-06-23 | 1996-08-14 | New York Blood Center Inc | SYSTEM FOR VIRAL INACTIVATION OF BLOOD |
| US6420570B1 (en) | 1993-06-28 | 2002-07-16 | Cerus Corporation | Psoralen compounds |
| US5399719A (en) | 1993-06-28 | 1995-03-21 | Steritech, Inc. | Compounds for the photodecontamination of pathogens in blood |
| US5625079A (en) | 1993-06-28 | 1997-04-29 | Cerus Corporation | Synthesizing psoralen compounds useful as intermediates |
| US6319662B1 (en) * | 1993-12-17 | 2001-11-20 | Baxter International Inc. | Method and apparatus for removing viral contaminants from a body fluid |
| WO1995018665A1 (en) * | 1994-01-10 | 1995-07-13 | Hemasure, Inc. | Device and process for removing leukocytes and viral inactivating agents from blood |
| US5639376A (en) * | 1994-01-10 | 1997-06-17 | Hemasure, Inc. | Process for simultaneously removing leukocytes and methylene blue from plasma |
| DE4444045C2 (de) * | 1994-12-10 | 1997-04-17 | Behringwerke Ag | Verfahren zur Inaktivierung von Viren mit Hilfe von Acridin oder Acridinderivaten |
| US6544727B1 (en) | 1995-06-07 | 2003-04-08 | Cerus Corporation | Methods and devices for the removal of psoralens from blood products |
| AT406778B (de) * | 1996-04-09 | 2000-09-25 | Immuno Ag | Verfahren zur desintegration von nucleinsäuren und herstellung von qualitätsgesicherten biologischen produkten |
| JP2000512762A (ja) * | 1996-06-17 | 2000-09-26 | マーキュリー ダイアグノスティックス インコーポレイテッド | 電気化学テスト装置および関連する方法 |
| US6190609B1 (en) | 1996-11-19 | 2001-02-20 | Baxter International Inc. | Methods and apparatus for inactivating contaminants in biological fluid |
| US5922278A (en) * | 1996-11-19 | 1999-07-13 | Baxter International Inc. | Method and apparatus for inactivating contaminants in biological fluid |
| US20010009756A1 (en) | 1998-01-06 | 2001-07-26 | Derek Hei | Flow devices for the reduction of compounds from biological compositions and methods of use |
| US20010018179A1 (en) | 1998-01-06 | 2001-08-30 | Derek J. Hei | Batch devices for the reduction of compounds from biological compositions containing cells and methods of use |
| DE69819360T2 (de) * | 1997-11-20 | 2004-08-19 | Cerus Corp., Concord | Neue psoralene zur inaktivierung von pathogenen |
| US7611831B2 (en) | 1998-01-06 | 2009-11-03 | Cerus Corporation | Adsorbing pathogen-inactivating compounds with porous particles immobilized in a matrix |
| US6610436B1 (en) | 1998-09-11 | 2003-08-26 | Gore Enterprise Holdings | Catalytic coatings and fuel cell electrodes and membrane electrode assemblies made therefrom |
| DE19904088A1 (de) | 1999-02-02 | 2000-09-07 | Fressenius Hemocare Gmbh | Schlauchset für einen Zellseparator zum Separieren von Blut in seine Komponenten und Verfahren zum Separieren von Blut in seine Komponenten |
| DE19914850A1 (de) * | 1999-04-01 | 2000-10-05 | Gerhard Saalmann | Vorrichtung und Verfahren zur Inaktivierung von Viren in biologischen Flüssigkeiten |
| US6565802B1 (en) | 1999-06-03 | 2003-05-20 | Baxter International Inc. | Apparatus, systems and methods for processing and treating a biological fluid with light |
| US6268120B1 (en) | 1999-10-19 | 2001-07-31 | Gambro, Inc. | Isoalloxazine derivatives to neutralize biological contaminants |
| US7648699B2 (en) | 2000-06-02 | 2010-01-19 | Caridianbct Biotechnologies, Llc | Preventing transfusion related complications in a recipient of a blood transfusion |
| US7985588B2 (en) | 2000-06-02 | 2011-07-26 | Caridianbct Biotechnologies, Llc | Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light |
| TW590780B (en) | 2000-06-02 | 2004-06-11 | Gambro Inc | Additive solutions containing riboflavin |
| US9044523B2 (en) | 2000-06-15 | 2015-06-02 | Terumo Bct, Inc. | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
| DE10031851B4 (de) * | 2000-07-04 | 2005-10-13 | Blutspendedienst der Landesverbände des Deutschen Roten Kreuzes Niedersachsen, Sachsen-Anhalt, Thüringen, Oldenburg und Bremen gGmbH | Photodynamische Behandlung und UV-B-Bestrahlung einer Thrombozyten-Suspension |
| EP1469891B1 (en) * | 2002-02-01 | 2009-04-15 | CaridianBCT Biotechnologies, LLC | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
| US10478514B2 (en) * | 2014-05-23 | 2019-11-19 | Ovik Leonardovich Mkrtchyan | Methods for inactivating, on medical instruments and devices, viruses containing RNA and DNA, and apparatuses for implementating same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2827109C2 (de) * | 1977-06-24 | 1986-10-30 | Asahi Kasei Kogyo K.K., Osaka | Verfahren und Vorrichtung zur Abtrennung von organischen Verbindungen von Plasmaproteinen des Blutes |
| JPS5665071A (en) * | 1979-11-01 | 1981-06-02 | Asahi Chem Ind Co Ltd | Photo-oxidation treating agent |
| US4748120A (en) * | 1983-05-02 | 1988-05-31 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
| US4727027A (en) * | 1983-05-02 | 1988-02-23 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
| JPS61275228A (ja) * | 1985-03-14 | 1986-12-05 | バクスタ−、トラベノ−ル、ラボラトリ−ズ、インコ−ポレイテツド | 治療用タンパク組成物中のビ−ルスの光動的不活性化 |
| US4775625A (en) * | 1986-11-21 | 1988-10-04 | The Medical College Of Wisconsin, Inc. | Inactivating enveloped viruses with a merocyanine dye |
| DE3717951C1 (de) * | 1987-05-25 | 1988-11-24 | Shanmugam Murugavel | Verwendung von Silica-Gel zur Entgiftung von Blut |
| US4878891A (en) * | 1987-06-25 | 1989-11-07 | Baylor Research Foundation | Method for eradicating infectious biological contaminants in body tissues |
| DE3805459A1 (de) * | 1988-02-22 | 1989-08-31 | Biotest Pharma Gmbh | Verfahren zur sterilisation von blut, plasma, blut- und plasmaderivaten, zellsuspensionen oder dgl. |
| US5149718A (en) * | 1989-01-19 | 1992-09-22 | New York University | Biological fluid purification system |
| DE471794T1 (de) * | 1989-05-11 | 1992-07-23 | Oklahoma Medical Research Foundation, Oklahoma, Okla. | Antivirale therapie unter verwendung von thiazin- und xanthenfarbstoffen. |
-
1989
- 1989-09-13 DE DE3930510A patent/DE3930510A1/de not_active Withdrawn
-
1990
- 1990-09-08 WO PCT/DE1990/000691 patent/WO1991003933A1/de active IP Right Grant
- 1990-09-08 EP EP90913337A patent/EP0491757B2/de not_active Expired - Lifetime
- 1990-09-08 JP JP2512344A patent/JP2965695B2/ja not_active Expired - Fee Related
- 1990-09-08 AT AT90913337T patent/ATE161681T1/de not_active IP Right Cessation
- 1990-09-08 DE DE122008000026C patent/DE122008000026I2/de active Active
- 1990-09-08 ES ES90913337T patent/ES2113347T5/es not_active Expired - Lifetime
- 1990-09-08 HU HU9200627A patent/HU215131B/hu unknown
- 1990-09-08 EP EP19930120072 patent/EP0593098A3/de not_active Withdrawn
- 1990-09-08 DE DE59010793T patent/DE59010793D1/de not_active Expired - Lifetime
- 1990-09-08 DK DK90913337T patent/DK0491757T4/da active
- 1990-09-08 AU AU63391/90A patent/AU635068B2/en not_active Expired
- 1990-09-08 CA CA002065842A patent/CA2065842C/en not_active Expired - Lifetime
-
1992
- 1992-03-03 NO NO920834A patent/NO300911B1/no not_active IP Right Cessation
- 1992-03-05 FI FI920981A patent/FI99192C/fi active
- 1992-03-12 RU SU925011884A patent/RU2036235C1/ru active
- 1992-03-13 CS CS92766A patent/CS76692A3/cs unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPH05500366A (ja) | 1993-01-28 |
| ATE161681T1 (de) | 1998-01-15 |
| JP2965695B2 (ja) | 1999-10-18 |
| HU215131B (hu) | 1998-09-28 |
| DE122008000026I2 (de) | 2011-05-05 |
| DK0491757T4 (da) | 2002-04-22 |
| EP0593098A3 (de) | 1994-04-27 |
| NO920834D0 (no) | 1992-03-03 |
| DE122008000026I1 (de) | 2008-08-21 |
| ES2113347T5 (es) | 2002-09-16 |
| CA2065842A1 (en) | 1991-03-14 |
| AU6339190A (en) | 1991-04-18 |
| DE3930510A1 (de) | 1991-03-21 |
| WO1991003933A1 (de) | 1991-04-04 |
| RU2036235C1 (ru) | 1995-05-27 |
| EP0491757B1 (de) | 1998-01-07 |
| DK0491757T3 (da) | 1998-09-07 |
| EP0491757B2 (de) | 2002-01-09 |
| FI920981A0 (fi) | 1992-03-05 |
| EP0593098A2 (de) | 1994-04-20 |
| HU9200627D0 (en) | 1992-05-28 |
| DE59010793D1 (de) | 1998-02-12 |
| HUT60142A (en) | 1992-08-28 |
| CS76692A3 (en) | 1992-08-12 |
| EP0491757A1 (de) | 1992-07-01 |
| FI99192B (fi) | 1997-07-15 |
| ES2113347T3 (es) | 1998-05-01 |
| NO920834L (no) | 1992-03-03 |
| AU635068B2 (en) | 1993-03-11 |
| FI99192C (fi) | 1997-10-27 |
| CA2065842C (en) | 1999-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO300911B1 (no) | Fremgangsmåte for inaktivering av virus i blod og blodprodukter | |
| AU698154B2 (en) | System for viral inactivation of blood | |
| Matthews et al. | Photodynamic therapy of viral contaminants with potential for blood banking applications | |
| Wagner et al. | Red cell alterations associated with virucidal methylene blue phototreatment | |
| EP0368902B1 (en) | Method for eradicating infectious contaminants in tissues | |
| Wagner | Virus inactivation in blood components by photoactive phenothiazine dyes | |
| US5545516A (en) | Inactivation of extracellular enveloped viruses in blood and blood components by phenthiazin-5-ium dyes plus light | |
| EP0457196B1 (en) | Photodynamic inactivation of viruses in cell-containing compositions | |
| Seghatchian et al. | Pathogen-reduction systems for blood components: the current position and future trends | |
| CA2225470C (en) | Method and apparatus for inactivating contaminants in blood products | |
| CA2154761A1 (en) | Method and apparatus for treating a body fluid | |
| Smetana et al. | Photodynamic inactivation of herpes viruses with phthalocyanine derivatives | |
| Allen et al. | Sulfophthalocyanines for photodynamic inactivation of viruses in blood products: effect of structural modifications | |
| Wagner et al. | Differential sensitivities of viruses in red cell suspensions to methylene blue photosensitization | |
| PT633721E (pt) | Descontaminacao de plaquetas com 8-metoxipsoraleno | |
| EP0124363A2 (en) | Photochemical decontamination treatment of whole blood or blood components | |
| US6348309B1 (en) | Process for inactivating viruses in blood and blood products | |
| Friedman et al. | Reducing the infectivity of blood components what we have learned | |
| RU2558432C2 (ru) | Способ инактивации патогенов | |
| WO2000034446A1 (en) | Inactivation of non-enveloped viruses | |
| Acquaye et al. | Isolation and quantitation of human erythrocyte deformability classes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |